JP2011509308A5 - - Google Patents

Info

Publication number

JP2011509308A5

JP2011509308A5 JP2010542376A JP2010542376A JP2011509308A5 JP 2011509308 A5 JP2011509308 A5 JP 2011509308A5 JP 2010542376 A JP2010542376 A JP 2010542376A JP 2010542376 A JP2010542376 A JP 2010542376A JP 2011509308 A5 JP2011509308 A5 JP 2011509308A5

Authority

JP

Japan

Prior art keywords

compound according

composition

item

hydroxy

compound

Prior art date

2009-01-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 57
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
• 239000000203 mixture Substances 0.000 claims description 12
• 229910052739 hydrogen Inorganic materials 0.000 claims description 10
• 239000001257 hydrogen Substances 0.000 claims description 10
• 241000124008 Mammalia Species 0.000 claims description 8
• 201000010099 disease Diseases 0.000 claims description 8
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
• 208000035475 disorder Diseases 0.000 claims description 6
• 230000001404 mediated effect Effects 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 4
• 230000003463 hyperproliferative effect Effects 0.000 claims description 4
• 230000002401 inhibitory effect Effects 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 150000003839 salts Chemical class 0.000 claims description 4
• 238000006467 substitution reaction Methods 0.000 claims description 4
• 238000002560 therapeutic procedure Methods 0.000 claims description 4
• FYEWVYNHLZNOSJ-NSISKUIASA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-[(1-hydroxy-2-methylpropan-2-yl)amino]propan-1-one Chemical compound C1([C@@H](CNC(C)(C)CO)C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)=CC=C(Cl)C=C1 FYEWVYNHLZNOSJ-NSISKUIASA-N 0.000 claims description 2
• HOJSWRWFMKOFFV-NSISKUIASA-N (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-[(2-hydroxy-2-methylpropyl)amino]propan-1-one Chemical compound C1([C@@H](CNCC(C)(C)O)C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)=CC=C(Cl)C=C1 HOJSWRWFMKOFFV-NSISKUIASA-N 0.000 claims description 2
• JVKUGJVIBUMCFL-WRWLIDTKSA-N (2s)-2-[3-fluoro-4-(trifluoromethyl)phenyl]-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-[(1-hydroxy-2-methylpropan-2-yl)amino]propan-1-one Chemical compound C1([C@@H](CNC(C)(C)CO)C(=O)N2CCN(CC2)C=2N=CN=C3[C@H](O)C[C@H](C=23)C)=CC=C(C(F)(F)F)C(F)=C1 JVKUGJVIBUMCFL-WRWLIDTKSA-N 0.000 claims description 2
• 206010028980 Neoplasm Diseases 0.000 claims description 2
• 201000011510 cancer Diseases 0.000 claims description 2
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
• 230000000694 effects Effects 0.000 claims description 2
• 230000002757 inflammatory effect Effects 0.000 claims description 2
• 230000000626 neurodegenerative effect Effects 0.000 claims description 2
• 150000002431 hydrogen Chemical class 0.000 claims 3
• 238000000034 method Methods 0.000 description 5
• 125000000217 alkyl group Chemical group 0.000 description 2
• 0 C[C@](C[C@](C1=NC*2)N=O)C1=C2C(CC1)CCN1C(C(CNCC(C)(C)O)c(cc1)ccc1O)=* Chemical compound C[C@](C[C@](C1=NC*2)N=O)C1=C2C(CC1)CCN1C(C(CNCC(C)(C)O)c(cc1)ccc1O)=* 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1